# A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

> **NCT02913443** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 18 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** RO7051790

## Key facts

- **NCT ID:** NCT02913443
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-20
- **Primary completion:** 2017-10-24
- **Final completion:** 2017-10-24
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913443, "A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT02913443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*